Head R - Search Results

1

Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Fay M, Head R, Martin J. Fay M, et al. Among authors: head r. J Neurooncol. 2015 Aug;124(1):1-3. doi: 10.1007/s11060-015-1816-z. Epub 2015 May 30. J Neurooncol. 2015. PMID: 26024652 Review.

2

The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay M, Martin JH. Hosein AN, et al. Among authors: head r. J Neurooncol. 2015 Apr;122(2):263-71. doi: 10.1007/s11060-014-1713-x. Epub 2015 Feb 4. J Neurooncol. 2015. PMID: 25648357

3

Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.

Rundle-Thiele D, Head R, Cosgrove L, Martin JH. Rundle-Thiele D, et al. Among authors: head r. Br J Clin Pharmacol. 2016 Feb;81(2):199-209. doi: 10.1111/bcp.12785. Epub 2015 Oct 30. Br J Clin Pharmacol. 2016. PMID: 26374633 Free PMC article. Review.

4

Valproate in Adjuvant Glioblastoma Treatment.

Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH. Fay MF, et al. Among authors: head r. J Clin Oncol. 2016 Sep 1;34(25):3105-7. doi: 10.1200/JCO.2016.67.2162. Epub 2016 Jun 13. J Clin Oncol. 2016. PMID: 27298401 No abstract available.

5

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Head RJ, Fay MF, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin JH. Head RJ, et al. Cancer Biol Ther. 2017 Dec 2;18(12):917-926. doi: 10.1080/15384047.2017.1385680. Epub 2017 Nov 20. Cancer Biol Ther. 2017. PMID: 29020502 Free PMC article. Review.

6

Buying time: Drug repurposing to treat the host in COVID-19H.

Martin JH, Clark J, Head R. Martin JH, et al. Among authors: head r. Pharmacol Res Perspect. 2020 Aug;8(4):e00620. doi: 10.1002/prp2.620. Pharmacol Res Perspect. 2020. PMID: 32578336 Free PMC article.

7

A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.

Martin JH, Head R. Martin JH, et al. Among authors: head r. Br J Clin Pharmacol. 2021 Mar;87(3):875-885. doi: 10.1111/bcp.14551. Epub 2020 Nov 18. Br J Clin Pharmacol. 2021. PMID: 32959913 Free PMC article. Review.

8

Obesity and COVID-19: renin-angiotensin as a mediator of morbidity and mortality.

Martin JH, Head RE. Martin JH, et al. Br J Nutr. 2022 May 14;127(9):1439-1440. doi: 10.1017/S0007114521001847. Epub 2021 Jun 3. Br J Nutr. 2022. PMID: 34078498 Free PMC article. No abstract available.

9

Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.

Islam S, Wang S, Bowden N, Martin J, Head R. Islam S, et al. Among authors: head r. Br J Clin Pharmacol. 2022 Jan;88(1):64-74. doi: 10.1111/bcp.14964. Epub 2021 Jul 9. Br J Clin Pharmacol. 2022. PMID: 34192364 Free PMC article. Review.

10

Did our pharmacological strategy for COVID-19 fail?

Martin JH, Baddeley M, Head R. Martin JH, et al. Among authors: head r. Pharmacol Res Perspect. 2021 Dec;9(6):e00866. doi: 10.1002/prp2.866. Pharmacol Res Perspect. 2021. PMID: 34708568 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters